ZNF860 Inhibitors
ZNF860 inhibitors encompass a range of chemical compounds designed to attenuate the functional activity of ZNF860 through various biochemical mechanisms. Compounds like PD 98059 and U0126 interfere with the MAPK/ERK and MEK1/2 pathways, respectively, which are critical for the regulation of transcription factors and their target genes. By disrupting these pathways, the inhibitors prevent the phosphorylation and activation of proteins that may be essential for ZNF860's gene regulatory functions, leading to a decrease in ZNF860-mediated transcriptional activity. Similarly, PI3K pathway inhibitors such as LY 294002 and Wortmannin hinder signaling cascades that influence transcriptional regulation, thereby reducing ZNF860's DNA-binding capacity and subsequent gene expression modulation. SP600125 and SB 203580 target the JNK and p38 MAP kinases, which link to transcriptional machinery that could cooperate with ZNF860; the inhibition of these kinases results in a diminished regulatory effect of ZNF860 on its target gene expression.
Additionally, inhibitors like Rapamycin, Chetomin, and Bortezomib impact cellular processes that indirectly modulate ZNF860 activity by altering its transcriptional environment. Rapamycin's mTOR inhibition affects cellular growth pathways that can lead to a subdued transcriptional role for ZNF860, while Chetomin disrupts HIF-1α interactions, thereby influencing hypoxia-driven gene expression that ZNF860 may be involved in. Proteasome inhibitors such as MG-132 and Bortezomib stabilize proteins that can compete with ZNF860 for binding sites, thereby reducing its functional influence. The action of Triptolide on HSP70 affects the folding and stability of proteins, which may include transcription factors that work alongside ZNF860, leading to an overall decrement in ZNF860's activity. Finally, Trichostatin A shifts the epigenetic landscape by inhibiting histone deacetylases, affecting the chromatin accessibility for ZNF860 and thus its ability to regulate gene expression, culminating in a comprehensive downregulation of ZNF860's transcriptional activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. Inhibition of the MEK interrupts downstream signaling leading to a decrease in transcription factor activity, including that of ZNF860, reducing its ability to regulate gene expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a potent inhibitor of the phosphoinositide 3-kinases (PI3K) pathway. PI3K signaling is crucial for many cellular processes, including the activation of certain zinc finger proteins. By inhibiting PI3K, LY 294002 indirectly reduces the functional activity of ZNF860 by affecting its DNA-binding capacity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in the AP-1 pathway that regulates gene expression. By inhibiting JNK, SP600125 may prevent the activation of transcription factors that work in concert with ZNF860, indirectly diminishing ZNF860's regulatory role in gene expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAP kinase. The p38 pathway is implicated in the regulation of transcription factors and subsequent gene expression. By blocking p38 MAP kinase, SB 203580 indirectly diminishes ZNF860's influence on gene expression by altering the transcriptional landscape it interacts with. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide is a diterpene triepoxide that inhibits heat shock protein 70 (HSP70). HSP70 is involved in the folding and stabilization of many proteins, including transcription factors. Triptolide's inhibition of HSP70 may indirectly lead to a decrease in ZNF860 activity by affecting its proper folding and function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. By stabilizing transcription factors that are ordinarily degraded, MG-132 may indirectly lead to a competitive inhibition of ZNF860's target gene binding, diminishing its functional activity in the cell. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that affects the PI3K/AKT/mTOR pathway, which is involved in cellular growth and transcriptional regulation. By inhibiting this pathway, rapamycin can indirectly diminish ZNF860's role in gene expression by altering the transcriptional environment in which it functions. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $186.00 $674.00 | 10 | |
Chetomin disrupts the interaction between hypoxia-inducible factor-1α (HIF-1α) and the transcriptional coactivator p300. This disruption can indirectly diminish the activity of ZNF860 by affecting the hypoxia response elements and their associated transcription factors, which may work in tandem with ZNF860. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor used to prevent the degradation of protein. By maintaining higher levels of regulatory proteins that may compete with ZNF860 for DNA binding, bortezomib can indirectly diminish ZNF860’s regulatory impact on gene expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream regulators of the ERK pathway. By inhibiting this pathway, U0126 indirectly diminishes the activity of ZNF860 by potentially altering the phosphorylation status of proteins that interact with or regulate ZNF860, thereby affecting its function. | ||||||